Full Press Release Details
Forward-Looking Statements This presentation and the accompanying verbal
remarks contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding data from the clinical trials for certain of ImmunityBio's product candidates, clinical trial
enrollment and results, the regulatory review process and timing 11/14/202 2 thereof, timing of regulatory submissions, timing of meetings with regulators, potential implications to be drawn from clinical trials, potential commercialization of
product candidates, ImmunityBio's product candidates as compared to existing treatment options, and intellectual property protection and patent life, among others. Statements that are not statements of historical fact are considered
forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates,"
"scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "seeks,"
"should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions
may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's
management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry
into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) whether the FDA will approve ImmunityBio's filed BLA and the risks and uncertainties associated with the regulatory approval
process, (ii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory
submissions, (iii) ImmunityBio's ability to retain and hire key personnel, (iv) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product
candidates, (v) ImmunityBio's ability to successfully commercialize its product candidates and uncertainties around regulatory reviews and approvals, (vi) ImmunityBio's ability to scale its manufacturing and commercial supply operations
for its product candidates and future approved products, (vii) ImmunityBio's ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies, and (viii) the unknown
future impact of the COVID-19 pandemic on certain clinical trials or their milestones and/or ImmunityBio's business operations or operating expenses. More details about these and other risks that may impact ImmunityBio's business are
described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on March 1, 2022 and the Company's Form 10-Q filed with the SEC on November 9,
2022, and in subsequent filings made by ImmunityBio with the SEC, which a re available on the SEC's website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date
hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information. 2 11/14/202 2
Background: History of Driving Shareholder Value in the
Biopharmaceutical Industry Through Innovation, Quality and Scale 2001 - 2008 2005 - 2010 American Pharmaceutical Partners (NASDAQ: APPX) Abraxis BioScience (NASDQ: ABII) One of the nation's largest injectable manufacturing
2005: Abraxane - Nation's first protein (albumin) 190 FDA approved dosage forms nanoparticle chemotherapy approved 2001: IPO NASDAQ: APPX, market cap $769M Abraxane approved for breast cancer, lung cancer and pancreatic cancer
with state-of-the-art global 2008: Safe supply of heparin during the heparin manufacturing plant for protein nanoparticles crisis in 2008 2010: Abraxis acquired by Celgene for $3.6 billion 2008: Fresenius SE acquired APPX for
$5.6 billion inclusive of CVRs 2020: Abraxane achieves Blockbuster status of over a $1 billion dollar in sales 2009: APPX products approached $800 million dollars in sales 2021: Abraxane global sales at Bristol Meyers Squibb
reached $1.2 billion dollars in sales 3 11/14/22
Background: History of Driving Shareholder Value in the
Biopharmaceutical Industry Through Innovation, Quality and Scale 2000 - 2010: American Pharmaceutical Partners (APP) and Abraxis BioScience (ABII) 2010 - 2020: Cancer Moonshot Initiative (QUILT Trials): The NANT Cancer Vaccine
Natural Killer Memory Killer (NK) Cell T Cell Scale in platforms and products across the immune system Crosstalk Killer Cells Dendritic Cell Scale in biological manufacturing capacity at GMP commercial level Scale in
exploratory clinical trials across multiple tumor types to validate the hypothesis 2021: Launch of ImmunityBio (NASDAQ: IBRX) Through Merger of NantKwest & NantCell 2021 - 2025: Registration Strategy and Anticipated Product
Launches Product Launches Indications: Bladder Cancer N-803 (Anktiva) Pancreatic Cancer PD-L1 t-haNK Lung Cancer Aldoxorubicin Glioblastoma hAd5 E6/E7 Head & Neck Cancer
hAd5 CEA, MUC1, Brachyury Lynch Syndrome (Prevention of Cancer) 4 11/14/22
Multi Billion Dollar Investment in Scale (2010 - 2022)
Immunotherapy Platform Scale Biological Manufacturing Scale Multiple Tumor Type Scale Plant 1 Plant 2 Plant 3 Fusion Proteins NK Cell Cancer Moonshot 2014 to 2020 & Cytokines Therapy Natural Killer Memory Killer (NK) Cell T Cell Crosstalk Killer
Cells Dendritic Cell Plant 5 Plant 6 Plant 4 NK-92 NK & T Cell Activators Subunit Protein Antigens Memory-Like Cytokine NK Plant 7 Plant 8 DAMP DNA Inducers Vaccine Aldoxorubicin hAd5 Adenovirus
Nanatinostat NASDAQ: IBRX Toll Receptor RNA Registration Strategy Activators Vaccine 2021 - 2025 Registration Trials Bladder Cancer Pancreatic Cancer Lung Cancer Self-Amplifying TLR 4, 7, 8, 9 Plant
10* Plant 9* Plant 11* Glioblastoma RNA (saRNA) Head & Neck Cancer Patent Terms 2038+ Lynch Syndrome Worldwide Patents Extending to 2035 and Beyond 5 11/14/22 *Through Potential Strategic Collaborators
Cancer Moonshot: Tipping the Scales From Immuno-Evasion to Immune
Activation Across Multiple Tumor Types The NANT Cancer Vaccine: QUILT Trials: 2014 - 2020 Red Green Natural Killer Memory Killer (Cancer Cell) (Normal Cell) Nine (NK) Cell T Cell Crosstalk Response Assessments IBRX Agents Dose Killer Cells CIS
Patient (intravesicular Papillary Ad-MUC1 Ad-MUC1 instillation) 24M W12 6M 9M 12M 15M 18M 21M Adeno Dendritic Cell Ad-Brachy Ad-Brachy Vaccines NASDAQ: IBRX 1 Pap CR* CR CR CR CR CR CR CR Ad-CEA Ad-CEA Registration Trials 100 g 2 Pap CR* CR CR
CR CR CR CR CR Bladder Cancer Ye-Brachy Ye-Brachy Pancreatic Cancer Yeast Lung Cancer 3 Pap CR* CR CR CR CR CR CR CR Ye-CEA Ye-CEA Tumor Targeted Off-the-Shelf Vaccines Glioblastoma Natural Killer Cells Head
& Neck Cancer Two Three Ye-Ras Ye-Ras 4 Pap IC CR* CR CR CR CR CR CR IBRX Agents IBRX Agents Lynch Syndrome One haNK haNK PD-L1 t-haNK PD-L1 t-haNK aNK NK Cell NK Cell NK Cell IBRX Agent 200 g 5 CIS IC IC IC CR CR CR CR 2021 - 2025
CR Registration Strategy N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 6 Pap CR* CR CR CR CR CR CR CR BCG BCG Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldox PD-1 Checkpoint Aldox 7 Pap CR* CR CR CR CR CR CR CR 2017
nd 2 Line st nd nd rd nd rd 1 Line 2 Line 2 Line 3 Line 3rd Line 2 & 3 Line Cancer Moonshot Cancer Moonshot Cancer Moonshot Metastatic NMIBC NMIBC Across Multiple Across Multiple 400 g or Greater Across Multiple Metastatic Metastatic Head
Merkel Cell 8 CIS CR* CR CR CR CR CR CR CR** Pancreatic Tumor Types Tumor Types Tumor Types Bladder Bladder Glioblastoma TNBC & Neck Carcinoma Cancer 9 Pap CR* CR CR CR CR CR CR CR 2014 2017 2015 2019 2019 2017 2017 2021 *CR termed as No
Recurrence (NR) in Papillary Disease **Negative Cystoscopy Inconclusive Cytology COMPLETE COMPLETE COMPLETE COMPLETE COMPLETE COMPLETE COMPLETE NADAQ: IBRX RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE NantCell & NantKwest Proof
of Concept: Complete Responses Across Multiple Tumor Types Merger 6 11/14/22
Cancer Moonshot: Tipping the Scales From Immuno-Evasion to Immune
Activation Across Multiple Tumor Types The NANT Cancer Vaccine: QUILT Trials: 2014 - 2020 Red Green Natural Killer Memory Killer (Cancer Cell) (Normal Cell) Nine (NK) Cell T Cell Crosstalk IBRX Agents Killer Cells Ad-MUC1 Ad-MUC1 Adeno Dendritic
Cell Ad-Brachy Ad-Brachy Vaccines NASDAQ: IBRX Ad-CEA Ad-CEA Registration Trials Bladder Cancer Ye-Brachy Ye-Brachy Pancreatic Cancer Yeast Lung Cancer Ye-CEA Ye-CEA Tumor Targeted Off-the-Shelf Vaccines Glioblastoma
Natural Killer Cells Head & Neck Cancer Two Three Ye-Ras Ye-Ras IBRX Agents IBRX Agents Lynch Syndrome One haNK haNK PD-L1 t-haNK PD-L1 t-haNK aNK NK Cell NK Cell NK Cell IBRX Agent 2021 - 2025 Registration Strategy N-803 N-803
N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 BCG BCG Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldox PD-1 Checkpoint Aldox nd 2 Line st nd nd rd nd rd 1 Line 2 Line 2 Line 3 Line 3rd Line Cancer Moonshot 2 & 3 Line Cancer
Moonshot Cancer Moonshot Metastatic Across Multiple NMIBC NMIBC Across Multiple or Greater Across Multiple Metastatic Metastatic Head Merkel Cell Tumor Types Pancreatic Tumor Types Tumor Types Bladder Bladder Glioblastoma TNBC & Neck Carcinoma
Cancer 2014 2017 2015 2019 2019 2017 2017 2021 COMPLETE COMPLETE COMPLETE COMPLETE PARTIAL COMPLETE COMPLETE NADAQ: IBRX RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE NantCell & NantKwest Proof of Concept: Complete Responses
Across Multiple Tumor Types Merger 7 11/14/22
Cancer Moonshot: Tipping the Scales From Immuno-Evasion to Immune
Activation Across Multiple Tumor Types The NANT Cancer Vaccine: QUILT Trials: 2014 - 2020 Red Green Natural Killer Memory Killer (Cancer Cell) (Normal Cell) Nine (NK) Cell T Cell Crosstalk IBRX Agents Killer Cells Ad-MUC1 Ad-MUC1 Adeno Dendritic
Cell Ad-Brachy Ad-Brachy Vaccines NASDAQ: IBRX Ad-CEA Ad-CEA Registration Trials Bladder Cancer Ye-Brachy Ye-Brachy Pancreatic Cancer Yeast Lung Cancer Ye-CEA Ye-CEA Tumor Targeted Off-the-Shelf Vaccines Glioblastoma
Natural Killer Cells Head & Neck Cancer Two Three Ye-Ras Ye-Ras spIND IBRX Agents IBRX Agents Lynch Syndrome One haNK haNK PD-L1 t-haNK PD-L1 t-haNK aNK NK Cell NK Cell NK Cell IBRX Agent 2021 - 2025 Registration Strategy N-803
N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 BCG BCG Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldox PD-1 Checkpoint Aldox nd 2 Line st nd nd rd nd rd 1 Line 2 Line 2 Line 3 Line 3rd Line Cancer Moonshot 2 & 3 Line
Cancer Moonshot Cancer Moonshot Metastatic Across Multiple NMIBC NMIBC Across Multiple or Greater Across Multiple Metastatic Metastatic Head Merkel Cell Tumor Types Pancreatic Tumor Types Tumor Types Bladder Bladder Glioblastoma TNBC & Neck
Carcinoma Cancer 2014 2017 2015 2019 2019 2017 2017 2021 spIND COMPLETE COMPLETE COMPLETE COMPLETE PARTIAL COMPLETE COMPLETE NADAQ: IBRX RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE NantCell & NantKwest Proof of Concept:
Complete Responses Across Multiple Tumor Types Merger 8 11/14/22
Cancer Moonshot: Tipping the Scales From Immuno-Evasion to Immune
Activation Across Multiple Tumor Types The NANT Cancer Vaccine: QUILT Trials: 2014 - 2020 th Red >5 Line Metastatic Green Natural Killer Memory Killer (Cancer Cell) Head & Neck (Normal Cell) Nine (NK) Cell T Cell Crosstalk IBRX Agents Killer
Cells Ad-MUC1 Ad-MUC1 Adeno Dendritic Cell Ad-Brachy Ad-Brachy Vaccines NASDAQ: IBRX Ad-CEA Ad-CEA Registration Trials Bladder Cancer Ye-Brachy Ye-Brachy Pancreatic Cancer Pre-Treatment Yeast th Lung C 5an Line cer Ye-CEA
Ye-CEA Tumor Targeted Off-the-Shelf Vaccines Glioblastoma Natural Killer Cells Head & Neck Cancer Two Three Ye-Ras Ye-Ras IBRX Agents IBRX Agents Lynch Syndrome One haNK haNK PD-L1 t-haNK PD-L1 t-haNK aNK NK Cell NK Cell
NK Cell IBRX Agent 2021 - 2025 Registration Strategy N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 N-803 BCG BCG Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldox PD-1 Checkpoint Aldox nd 2 Line st nd nd rd nd rd 1 Line 2
Line 2 Line 3 Line 3rd Line Cancer Moonshot 2 & 3 Line Post-Treatment Cancer Moonshot Cancer Moonshot Metastatic Across Multiple NMIBC NMIBC Across Multiple or Greater Across Multiple Metastatic Metastatic Head Merkel Cell COMPLETE Tumor Types
Pancreatic Tumor Types Tumor Types Bladder Bladder RESPONSE Glioblastoma TNBC & Neck Carcinoma Cancer After 2-Cycles 2014 2017 2015 2019 2019 2017 2017 2021 COMPLETE COMPLETE COMPLETE COMPLETE PARTIAL COMPLETE COMPLETE NADAQ: IBRX RESPONSE
RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE NantCell & NantKwest Proof of Concept: Complete Responses Across Multiple Tumor Types Merger 9 11/14/22
Cancer Moonshot: Tipping the Scales From Immuno-Evasion to Immune
Activation Across Multiple Tumor Types The NANT Cancer Vaccine: QUILT Trials: 2014 - 2020 Red Green 2021 - 2025 Natural Killer Memory Killer (Cancer Cell) (Normal Cell) Nine Registration Strategy (NK) Cell T Cell Crosstalk IBRX Agents Killer Cells
Registration Trials Ad-MUC1 Ad-MUC1 Adeno Dendritic Cell Ad-Brachy Ad-Brachy Bladder Cancer Vaccines Pancreatic Cancer Ad-CEA Ad-CEA Lung Cancer Ye-Brachy Ye-Brachy Glioblastoma Yeast Ye-CEA Ye-CEA Head &
Neck Cancer Tumor Targeted Off-the-Shelf Vaccines Natural Killer Cells Lynch Syndrome Two Three Ye-Ras Ye-Ras IBRX Agents IBRX Agents One haNK haNK PD-L1 t-haNK PD-L1 t-haNK aNK NK Cell NK Cell NK Cell IBRX Agent N-803 N-803 N-803 N-803
N-803 N-803 N-803 N-803 N-803 N-803 N-803 BCG BCG Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldoxorubicin Aldox PD-1 Checkpoint Aldox nd 2 Line st nd nd rd nd rd 1 Line 2 Line 2 Line 3 Line 3rd Line Cancer Moonshot 2 & 3 Line Cancer Moonshot
Cancer Moonshot Metastatic Across Multiple NMIBC NMIBC Across Multiple or Greater Across Multiple Metastatic Metastatic Head Merkel Cell Tumor Types Pancreatic Tumor Types Tumor Types Bladder Bladder Glioblastoma TNBC & Neck Carcinoma Cancer
2014 2017 2015 2019 2019 2017 2017 2021 COMPLETE COMPLETE COMPLETE COMPLETE PARTIAL COMPLETE COMPLETE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE RESPONSE NADAQ: IBRX NantCell & NantKwest Proof of Concept: Complete Responses Across
Multiple Tumor Types 10 Merger 11/14/22
Nov 2022 Registrational Development Strategy & Status
Investigational Anticipated Registrational Current Status Product Trial Indications (2023 - 2025) BCG-Unresponsive Bladder Cancer CIS BLA Filed, PDUFA May 2023 N-803 + BCG BCG-Unresponsive Bladder Cancer Papillary
Enrollment Completed, FDA Type B Meeting Scheduled Dec 2022 N-803 + BCG IL-15 Superagonist Anktiva, N-803 BCG Na ve Bladder Cancer CIS & Papillary Actively Enrolling N-803 + BCG nd 2 Line Lung Cancer
LungMAP Actively Enrolling, Multi-Center Trial N-803 + Checkpoint rd 3 Line Metastatic Pancreatic Cancer Enrollment Completed, FDA Type B Meeting Scheduled Dec 2022 N-803 + PD-L1 t-haNK + Aldox PD-L1 t-haNK nd >2
Line Glioblastoma Phase 2 Randomized Trial N-803 + PD-L1 t-haNK + Aldox rd 3 Line Metastatic Pancreatic Cancer Enrollment Completed, FDA Type B Meeting Scheduled Dec 2022 Aldoxorubicin N-803 + PD-L1 t-haNK + Aldox +
Adenovirus Vector HPV Head & Neck Cancer IND Anticipated 1H 2023 N-803 + hAd5 E6/E7 + PD-L1 t-haNK hAd5 E6/E7 Adenovirus Vector Lynch Syndrome - Prevention of Colon Cancer FDA / IRB Authorized: Initiation of
Multi-Center Trial hAd5 CEA, MUC1, N-803 + hAd5 CEA, MUC1, Brachyury Anticipated Q1 2023. NIH Sponsored Trial Brachyury 11 11/14/22
Orchestrating the Immune System Late-Stage U.S. Clinical Trial Updates:
First-in-Class Comprehensive Platforms NK + T Cells Bladder Cancer Anktiva (N-803) Pancreatic Cancer Natural Killer Cells PD-L1 t-haNK Lung Cancer DAMP Inducers Head & Neck Cancer
Aldoxorubicin Lynch Syndrome Memory B & T Cells Adenovirus (hAd5) 12 11/14/22
Orchestrating the Immune System Late-Stage U.S. Clinical Trial Updates:
First-in-Class Comprehensive Platforms NK + T Cells Bladder Cancer Anktiva (N-803) Pancreatic Cancer Natural Killer Cells PD-L1 t-haNK Lung Cancer DAMP Inducers Head & Neck Cancer
Aldoxorubicin Lynch Syndrome Memory B & T Cells Adenovirus (hAd5) 13 11/14/22
N-803 (Anktiva) Potentiates the NK Cell Induced Immunogenic Cell Death
in a BCG Infected Bladder Cancer Cell BCG Unresponsive Infected Stressed Cell N-803 (IL-15) Activation of Immunogenic NMIBC Cell Expressing Recruiting NK & T Cells Ligands for NK NK & T Cells Cell Death to Infected Cell QUILT 3032 & T
Cell BCG Infection N-803 Immunogenic Cell BCG N-803 NK & T Cell Death Long Term Induced + BCG Activation Stress Synergy Memory Durable Complete BCG + IL-15 Administered Intravesicalily Remission N-803 Trained Macrophage T Cell NK Cell T Cell
Infected Cell NK Cell N-803 Expanded & Activated NK & T Cells N-803 BCG Anktiva 14 N-803 is Investigational: Safety and Efficacy have Not been Established. 11/14/22
Summary of Efficacy of N-803 + BCG Published November 10, 2022 71% CR
Rate At Any Time 62% 53% 12 Months 24 Months Complete Response Complete Response 90% 26.6 89% Avoidance of Months Median Cystectomy Free Cystectomy Duration of CR At 24 Months DOI: https://doi.org/10.1056/EVIDoa2200167 In Responders "NEJM
Evidence presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making." 15 N-803 is Investigational: Safety and Efficacy have Not been Established. 11/14/22
Complete Response Rate (CRR) Across Subgroups Response rates for
subgroups are shown. The vertical dashed line represents the threshold required for the lower limit of the 95% confidence interval (CI) to meet the primary end point. BCG-unresp. Given BCG' represents patients previously defined as